Ok, ham as it may be, the calculations are based weekly low-high returns.What I mean by this is I took the low from the weekly lowest low just after the first Phase I results 10-16-98. Then the high from the highest weekly high 02-05-99. Those two figures ($28.00 / $3.50=8, 8-1=7) the difference between the two. Applied that finding to the present data. (Lowest weekly low 04-23-99; $10.75 X 7=75.25) Also, applying similar data findings from Immunex (A similar pharmaceutical research co) and came up with the figure $56.00 a share.This is NOT definite! The stock may or may not reach $56.00 a share after the projected release in late January, early February. That projection is based on good, encouraging news.However, the company is run by a very good team of professionals and the stock is being picked up by investment funds. (That stabilizes the stock price.) I will also say that like, Immunex, the stock will rocket when either T-20 or T-1249 is brought to market. That is after the products have gone through successful FDA tests. That is where the gamble is, will Trimeris's products succeed?I personally hope they will. Their concepts in medicine are radical yet make complete sense to me. I am however, not a doctor nor am I fighting HIV. After reviewing their projected projects and their past performance I feel good will and I am betting they will succeed!That is my two cents. (If it is worth that much.)Fool on!
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rat